NCI Annual Plan & Budget Proposal for Fiscal Year 2023. NCI continually pursues new and emerging scientific opportunities that, with further investment, would catalyze additional progress in cancer research.
The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven dulloblastoma
The Largest dulloblastoma Trial Makes Monumental Strides Forward for Cancer Research, Increases Survival in Children by 19 Percent
Scientists from Queen Mary University of London, funded by the charity Brain Tumour Research, have found a new way to starve cancerous brain tumour cells of energy in order to prevent further growth.
Curemedullo Is A Division Of The Carson Leslie Foundation ©2021 All rights reserved. The Carson Leslie Foundation (CLF) is a registered 501(c)(3) charity organization. Please note that cureMEdullo provides this information for the benefit of the medulloblastoma and childhood cancer community. cureMEdullo and CLF are not medical providers or a health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.